文献速递糖尿病

七种2型糖尿病风险评分在CoLaus人群队列中的验证

Validation of Seven Type 2 Diabetes Mellitus Risk Scores in a Population-Based Cohort: The CoLaus Study.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

在瑞士CoLaus研究5131名35–75岁参与者中验证七种2型糖尿病风险评分对10年发病的预测效度,平均随访10.9年,405人(7.9%)发生T2DM。Kahn CB评分AUC最高(0.866 [0.849-0.883]),FINDRISC次之(0.818 [0.798-0.838]),Griffin最低(0.740 [0.718-0.762])。Kahn CB和FINDRISC表现最佳,前者需采血更适于临床,后者可用于流行病学场景。

要点

  • Kahn CB评分区分度最高,AUC 0.866,但需血液检测。
  • FINDRISC评分AUC 0.818,无需采血,适合流行病学筛查。
  • Griffin评分AUC最低0.740,高危人群占比13.7%。

核心结论

  • 七种评分中Kahn CB与FINDRISC预测10年T2DM发病表现最佳。
  • FINDRISC可用于流行病学场景,Kahn CB因需采血限于临床场景。

研究设计与样本

  • 前瞻性人群队列CoLaus研究,纳入瑞士洛桑5131名35–75岁参与者(55%女性)。
  • 基线调查2003–2006年,平均随访10.9年,验证五种临床评分和两种临床+生物学评分。

主要发现

  • 随访期间405人(7.9%)发生T2DM。
  • 高危参与者总体 prevalence 从Griffin评分的13.7%到Balkau评分的43.3%。
  • 发病者中高危 prevalence 从Griffin评分的34.6%到Kahn CB评分的82.0%。
  • Kahn CB的AUC为0.866(95%CI 0.849–0.883),FINDRISC为0.818(95%CI 0.798–0.838),Griffin最低为0.740(95%CI 0.718–0.762)。
  • 除Griffin和Kahn C评分(敏感性)及Balkau评分(特异性)外,敏感性和特异性均高于70%;需筛查人数从Kahn CB的15.5到Griffin的36.7。

临床怎么用

  • 流行病学筛查可优先选用无需采血的FINDRISC评分。
  • 临床场景需更高区分度时可选用Kahn CB评分,但需血液检测。

局限性

  • 研究基于瑞士单一州人群,外推至其他人群需谨慎。
  • 原文未报告评分的校准度指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To assess the validity of seven type 2 diabetes mellitus (T2DM) risk scores in predicting the 10-year incidence of T2DM in a Swiss population-based study. METHODS: The prospective study included 5131 participants (55% women, age range 35 to 75 years) living in Lausanne, Switzerland. The baseline survey was conducted between 2003 and 2006, and the average follow-up was 10.9 years. Five clinically-based scores (the Balkau, Kahn clinical, Griffin, Swiss Diabetes Association [SDAS], and Finnish Diabetes Risk Score [FINDRISC]) and two clinically and biologically based scores (the Kahn CB and Wilson) were tested. RESULTS: 405 (7.9%) participants developed T2DM. The overall prevalence of participants at high risk ranged from 13.7% for the Griffin score to 43.3% for the Balkau score. The prevalence of participants at high risk among those who developed T2DM ranged from 34.6% for the Griffin score to 82.0% for the Kahn CB score. The Kahn CB score had the highest area under the ROC (value and 95% confidence interval: 0.866 [0.849-0.883]), followed by the FINDRISC (0.818 [0.798-0.838]), while the Griffin score had the lowest (0.740 [0.718-0.762]). Sensitivities and specificities were above 70%, except for the Griffin and the Kahn C scores (for sensitivity) and the Balkau score (for specificity). The numbers needed to screen ranged from 15.5 for the Kahn CB score to 36.7 for the Griffin score. CONCLUSION: The Kahn CB and the FINDRISC scores performed the best out of all the scores. The FINDRISC score could be used in an epidemiological setting, while the need for blood sampling for the Kahn CB score restricts its use to a more clinical setting.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kraege V, Fabecic J, Marques-Vidal P, et al. Validation of Seven Type 2 Diabetes Mellitus Risk Scores in a Population-Based Cohort: The CoLaus Study. J Clin Endocrinol Metab. 2020. PMID: 31781764. doi:10.1210/clinem/dgz220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。